Provided by Tiger Fintech (Singapore) Pte. Ltd.

CASI Pharmaceuticals

2.23
+0.15507.49%
Post-market: 2.230.00000.00%18:12 EDT
Volume:7.55K
Turnover:16.79K
Market Cap:34.47M
PE:-1.00
High:2.40
Open:2.04
Low:2.04
Close:2.07
Loading ...

CASI Pharmaceuticals Secures Interim Relief in Juventas Dispute

TIPRANKS
·
10 Feb

This CASI Pharmaceuticals Insider Increased Their Holding By 65% Last Year

Simply Wall St.
·
06 Feb

CASI Pharmaceuticals Faces Asset Freezing Amid Arbitration Dispute

TIPRANKS
·
21 Jan

CASI Pharmaceuticals: Fourth Intermediate People S Court of Beijing Municipality, Granted Juventas Application to Freeze Co's Assets

THOMSON REUTERS
·
21 Jan

CASI Pharmaceuticals Inc: Receives Asset Freezing Order From Court of P.r. China

THOMSON REUTERS
·
21 Jan

CASI Pharmaceuticals: First Patient Dosed in Phase 1/2 Clinical Trial of Cid-103 in Immune Thrombocytopenia

THOMSON REUTERS
·
06 Jan

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

ACCESSWIRE
·
06 Jan

BRIEF-CASI Pharmaceuticals Announces Clinical Hold Of CID-103

Reuters
·
26 Dec 2024

BUZZ-Casi Pharmaceuticals falls after FDA puts experimental antibody drug on hold

Reuters
·
26 Dec 2024

CASI Pharmaceuticals Faces Clinical Hold on CID-103 by FDA

TIPRANKS
·
26 Dec 2024

CASI Pharmaceuticals: FDA Plans to Provide Formal Written Response Before Statutory Deadline

THOMSON REUTERS
·
26 Dec 2024

CASI Pharmaceuticals Inc: Announces Clinical Hold of Cid-103 for Antibody Mediated Rejection (Amr) of Kidney Transplant

THOMSON REUTERS
·
26 Dec 2024

CASI Pharmaceuticals: Cid-103 Ind Application Supporting Phase 1-2 Study of Cid-103 in Adults With Chronic Immune Thrombocytopenia Remains Open

THOMSON REUTERS
·
26 Dec 2024

Casi Pharmaceuticals files $200M mixed securities shelf

TIPRANKS
·
21 Dec 2024

BRIEF-Casi Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $200 Million- SEC Filing

Reuters
·
21 Dec 2024

CASI Pharmaceuticals Faces Evomela® License Termination Dispute

TIPRANKS
·
16 Dec 2024